• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

    7/3/24 8:00:13 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADCT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Redmile Group, LLC

    (Last) (First) (Middle)
    ONE LETTERMAN DRIVE, BUILDING D
    SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ADC Therapeutics SA [ ADCT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/01/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Shares, par value CHF 0.08 per share 07/01/2024 P 400,000 A $2.81 15,669,217 I See Footnotes(1)(2)
    Common Shares, par value CHF 0.08 per share 07/01/2024 P 400,000 A $2.81 12,995,040 D(2)(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Redmile Group, LLC

    (Last) (First) (Middle)
    ONE LETTERMAN DRIVE, BUILDING D
    SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Green Jeremy

    (Last) (First) (Middle)
    C/O REDMILE GROUP, LLC (NY OFFICE)
    45 W. 27TH STREET, FLOOR 11

    (Street)
    NEW YORK NY 10001

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    RedCo II Master Fund, L.P.

    (Last) (First) (Middle)
    C/O REDMILE GROUP, LLC. ONE LETTERMAN
    DRIVE, BUILDING D, SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. These securities are directly owned by certain private investment vehicles and sub-advised accounts managed by Redmile Group, LLC ("Redmile"), including RedCo II Master Fund, L.P. ("RedCo II" and collectively with the other private investment vehicles and sub-advised accounts managed by Redmile, the "Redmile Clients"). Redmile may be deemed to beneficially own the reported securities as investment manager of the Redmile Clients.
    2. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green (collectively with RedCo II, the "Reporting Persons") disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    3. These securities are directly owned by RedCo II and this transaction is a repetition of the same transaction disclosed above in the first row to disclose this fund's direct ownership.
    Remarks:
    The purchases reported herein were effected within a period of less than six months from deemed sales reported in the Form 4 filed by the Reporting Persons on February 9, 2024. However, the purchases reported herein were effected at a price higher than certain previous deemed purchases that were also reported in the Form 4 filed February 9, 2024, such that no additional profits have been earned by the Reporting Persons, and so the Reporting Persons have no additional liability under Section 16(b).
    By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC 07/03/2024
    /s/ Jeremy Green, Managing Member of RedCo II (GP), LLC, the General Partner of RedCo II Master Fund, L.P. 07/03/2024
    /s/ Jeremy Green 07/03/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ADCT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADCT

    DatePrice TargetRatingAnalyst
    11/8/2024$6.00Overweight
    Stephens
    5/30/2024Overweight
    Cantor Fitzgerald
    3/28/2024$11.00Buy
    Guggenheim
    8/10/2023Underweight → Neutral
    JP Morgan
    4/24/2023$7.00 → $2.00Neutral → Underperform
    BofA Securities
    12/6/2022$12.00Overweight
    CapitalOne
    11/9/2022$14.00 → $7.00Buy → Neutral
    BofA Securities
    9/21/2022$5.00Overweight
    JP Morgan
    More analyst ratings

    $ADCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on ADC Therapeutics with a new price target

    Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00

    11/8/24 7:32:36 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on ADC Therapeutics

    Cantor Fitzgerald initiated coverage of ADC Therapeutics with a rating of Overweight

    5/30/24 7:26:04 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on ADC Therapeutics with a new price target

    Guggenheim initiated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $11.00

    3/28/24 7:31:32 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:04:01 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:03:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:

    4/23/21 1:46:03 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

    ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients Expansion to 100 r/r DLBCL patients underway in LOTIS-7 Phase 1b trial; Additional data to be shared in second half of 2025 LOTIS-5 Phase 3 trial expected to reach prespecified progression-free survival (PFS) events by end of 2025; update to follow once data are available Completed $100 million private placement extending expected cash runway into 2028 LAUSANNE, Switzerland, Aug. 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of ant

    8/12/25 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

    LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the e

    8/5/25 4:05:00 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

    LAUSANNE, Switzerland, Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 127,000 of the Company's common shares to three new employees on August 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to moti

    8/1/25 4:05:00 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Redmile Group, Llc bought $609,000 worth of shares (200,000 units at $3.04) (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    12/13/24 9:00:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    7/3/24 8:00:13 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by ADC Therapeutics SA

    SCHEDULE 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    8/14/25 4:15:34 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by ADC Therapeutics SA

    S-8 - ADC Therapeutics SA (0001771910) (Filer)

    8/12/25 5:10:03 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by ADC Therapeutics SA

    10-Q - ADC Therapeutics SA (0001771910) (Filer)

    8/12/25 4:12:02 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Leadership Updates

    Live Leadership Updates

    View All

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

    £90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi

    7/8/24 2:00:00 AM ET
    $ADCT
    $CG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

    LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th

    6/27/24 7:15:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Financials

    Live finance-specific insights

    View All

    ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

    ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients Expansion to 100 r/r DLBCL patients underway in LOTIS-7 Phase 1b trial; Additional data to be shared in second half of 2025 LOTIS-5 Phase 3 trial expected to reach prespecified progression-free survival (PFS) events by end of 2025; update to follow once data are available Completed $100 million private placement extending expected cash runway into 2028 LAUSANNE, Switzerland, Aug. 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of ant

    8/12/25 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

    LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the e

    8/5/25 4:05:00 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

    ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable safety profile Company expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg dose Company to host conference call today at 8:00 a.m. ET/2:00 p.m. CEST LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of

    6/12/25 6:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Squarer Ron covered exercise/tax liability with 15,184 shares, decreasing direct ownership by 14% to 93,627 units (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    6/17/25 5:03:44 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sandor Victor covered exercise/tax liability with 12,600 shares, decreasing direct ownership by 10% to 108,286 units (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    6/17/25 5:03:18 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Monges Viviane covered exercise/tax liability with 2,584 shares, decreasing direct ownership by 2% to 144,043 units (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    6/17/25 5:02:50 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/14/24 9:00:57 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/13/24 8:58:56 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/13/24 8:30:55 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care